Want to see SER full AI Analyst Report?
SER Stock Chart & Stats
$2.07
-$0.02(-0.96%)
At close: 4:00 PM EDT
$2.07
-$0.02(-0.96%)
Day’s Range― - ―
52-Week Range$1.22 - $7.92
Previous CloseN/A
Volume44.32K
Average Volume (3M)24.47K
Market Cap
$69.09M
Enterprise Value$11.97
Total Cash (Recent Filing)$23.02M
Total Debt (Recent Filing)$3.21M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 18, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding25,400,473
10 Day Avg. Volume14,098
30 Day Avg. Volume24,472
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-526.02
Price to Sales (P/S)0.00
P/FCF Ratio-1.08
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside358.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt gives Serina greater financial flexibility than a highly leveraged biotech and limits near-term interest burden. This supports the company’s ability to direct available capital toward clinical development, although it does not eliminate its need for future funding.
Experienced Board AdditionAdding a director with pharmaceutical commercialization and financing experience strengthens oversight as Serina advances SER-252 and its platform. The expertise may improve partnering, development and corporate strategy over the next several quarters.
Potentially Scalable Drug-delivery PlatformA polymer-based delivery platform that can modify release, stability or tolerability could support multiple product opportunities rather than a single asset. If validated clinically, this architecture may broaden partnering and development options over time.
Bears Say
No Current Revenue And Deep LossesSerina has not established recurring commercial revenue, while substantial operating and net losses show that the business remains dependent on development investment. The collapse from $3.15M of 2023 revenue to near-zero in 2024 also indicates limited operating scale.
Persistent Cash BurnCash outflow closely tracks reported losses, demonstrating that weak profitability is translating into a real funding requirement rather than being mainly non-cash. Continued clinical development will therefore likely require external capital before products generate cash.
Material Future Dilution RiskExpanded issuance capacity gives Serina flexibility to fund operations, but it also creates substantial potential dilution for existing holders. That risk is heightened by ongoing losses, cash burn and historically unstable equity, which may force repeated financing.
Serina Therapeutics News
SER FAQ
What was Serina Therapeutics’s price range in the past 12 months?
Serina Therapeutics lowest stock price was $1.22 and its highest was $7.92 in the past 12 months.
What is Serina Therapeutics’s market cap?
Serina Therapeutics’s market cap is $69.09M.
When is Serina Therapeutics’s upcoming earnings report date?
Serina Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 89 days.
How were Serina Therapeutics’s earnings last quarter?
Serina Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.466 by -$0.084.
Is Serina Therapeutics overvalued?
According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued.
Does Serina Therapeutics pay dividends?
Serina Therapeutics does not currently pay dividends.
What is Serina Therapeutics’s EPS estimate?
Serina Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Serina Therapeutics have?
Serina Therapeutics has 25,400,473 shares outstanding.
What happened to Serina Therapeutics’s price movement after its last earnings report?
Serina Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.466. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Serina Therapeutics?
Currently, no hedge funds are holding shares in SER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Serina Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (358.94% Upside)
$9.50 (358.94% Upside)
Insider Transactions
Bought Shares
Worth $10.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
188.71%
Trailing 12-Months
Company Description
Serina Therapeutics
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
SER Stock 12 Month Forecast
Average Price Target
$9.50
▲(358.94% Upside)
Technical Analysis
Outlook Therapeutics
―
Skye Bioscience
―
Celularity
―
Barinthus Biotherapeutics
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
34.84% Insiders
0.78% Mutual Funds
4.10% Other Institutional Investors
59.62% Public Companies and
Individual Investors